在HFpEF中作为二次处理的Chlorthalidone?
1Division of Cardiovascular Medicine, Indiana University School of Medicine, Indianapolis.
The American journal of medicine
|September 28, 2024
概括
新的心力衰竭与保存喷射分数 (HFpEF) 治疗方法侧重于减少HFpEF发生率,而不是死亡率. 甲基可能为HFpEF管理提供一种低成本的替代方案,特别是对于那些无法买得起新药的患者.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 随着心脏衰竭的治疗策略与保存的喷射分数 (HFpEF) 正在发展.
- 最近的证据强调了在HFpEF管理中具有利尿性质的药物.
研究的目的:
- 审查HFpEF治疗中的当前问题.
- 探索甲作为一种具有成本效益的HFpEF疗法的潜在作用.
主要方法:
- 对HFpEF治疗疗效的文献综述.
- 对药物特性和患者群体的分析.
主要成果:
- 现在推用于HFpEF的利尿作用药物,主要是减少HFpEF发生率.
- 甲基在降低高血压患者心力衰竭发病率方面表现出有效性.
结论:
- 甲基,可能与矿物质皮质激素抗剂结合,为HFpEF提供了一个可行的,低成本的二次治疗选择.
- 建议在即将发布的HFpEF指南中考虑甲基,特别是对于那些对SGLT2抑制剂或finerenone等新疗法有财务或耐受性限制的患者.
相关概念视频
Heart Failure Drugs: Diuretics
349
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
349
Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
395
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
395
Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320
Antihypertensive Drugs: Thiazide-Class Diuretics
554
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
554


